Methyprylon

Methyprylon is a sedative and hypnotic medication that was introduced in the 1950s by Hoffmann-La Roche, a Swiss multinational healthcare company. It is classified under the category of nonbarbiturate hypnotic drugs. Methyprylon was primarily used for the treatment of insomnia and other sleep disorders. However, due to its potential for abuse and the availability of safer alternatives, it has been largely discontinued.

History

Methyprylon was first synthesized in the 1950s by Hoffmann-La Roche. It was marketed under the brand name Noludar and was widely used for its sedative and hypnotic properties. However, by the late 20th century, the use of Methyprylon had significantly declined due to the high risk of addiction and the development of safer alternatives.

Pharmacology

Methyprylon works by increasing the activity of GABA, a neurotransmitter in the brain that inhibits the activity of the nervous system. This results in a calming effect, which helps to induce sleep. However, prolonged use of Methyprylon can lead to tolerance and physical dependence.

Side Effects and Risks

Common side effects of Methyprylon include drowsiness, dizziness, and impaired coordination. More serious side effects can include respiratory depression, coma, and even death, particularly when the drug is combined with other central nervous system depressants like alcohol or opioids.

Due to its high potential for abuse and the availability of safer alternatives, Methyprylon is now rarely used. In many countries, including the United States, it is classified as a Schedule III drug under the Controlled Substances Act.

See Also

• Barbiturate
• Benzodiazepine
• Z-drug

This article is a stub related to pharmacology. You can help WikiMD by expanding it!